Topic: physician payments
A new study suggests that the consistency of payments from drugmakers to doctors matters the most when it comes to swaying prescribing habits.
The U.S. Senate has released a report on Insys that provides an insider’s view of a company leaning on physicians to help drive sales.
Under a bipartisan opioid bill finalized by Congress, drugmakers will have to disclose payments made to nurses and physician assistants as well.
CEO Pascal Soriot says his company will disclose doctor payments in an additional 11 countries by 2019, aiming to unveil all of them after that.
Doctors who got free meals, speaking fees and other payments from drugmakers also prescribed more opioids, a new analysis found.
Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.
Transparency hasn't made much of a difference when it comes to drug and device makers' payments to doctors, which amounted to $2.6 billion last year.
In Germany, a nonprofit is trying disclosure based on the honor system.
California lawmakers are weighing a bill that would cut off most drugmaker payments to physicians, including speaking fees for that staple of pharma marketing, the slideshow over dinner.
If a proposed change in the way Medicare pays for injected drugs that doctors give at their offices goes forward, some companies will be hit harder than others. And according to a new report, one drugmaker in particular is at risk: Regeneron. And that is because of its strength in the marketplace, Eylea.